Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rBV A/B Vaccine for Botulism Prevention
NCT01940315Phase 3Withdrawn
- Sponsor
- DynPort Vaccine Company
- Start
- Oct 2017
- Primary completion
- Mar 2019
- Modality
- Vaccines & Immunotherapeutics
01
Overview
A Phase 3 trial of recombinant botulinum vaccine A/B in botulism, sponsored by DynPort Vaccine Company. Planned start Oct 2017; status: withdrawn.
02
Drugs
recombinant botulinum vaccine A/B
03
Conditions
botulism
Beyond the preview
Go deeper on NCT01940315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01940315.